Date Range
toReport Types
Condition
See all (7)
Region of the Body
See all (8)
Specialties
See all (18)
Emerging Treatments
OE Recommends Topics
Multimedia
Journal
Conference Series
Evidence Series
Zoledronic acid for postmenopausal osteoporosis reduces fracture risk and improves BMD
J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 2010 Oct 5
Lumiracoxib is an effective drug for OA with GI safety profile comparable to Rofecoxib
BMC Musculoskelet Disord. 2008 Sep 8;9:118.
Zoledronic acid affects men and women similarly in increasing bone mass after hip fracture
J Am Geriatr Soc. 2011 Nov;59(11):2084-90. doi: 10.1111/j.1532-5415.2011.03666.x. Epub 2011 Oct 21
Canakinumab effective in treating systemic juvenile idiopathic arthritis
N Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099
Zoledronic acid in the prevention and treatment of glucocorticoid-induced osteoporosis
Lancet. 2009 Apr 11;373(9671):1253-63
Zoledronic acid has no continued benefit beyond 6 years for osteoporosis
J Bone Miner Res. 2015 May;30(5):934-44.
Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients
Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10
Zoledronic acid: best overall bisphosphonate treatment for osteoporosis fractures
Semin Arthritis Rheum. 2011 Feb;40(4):275-84.e1-2.
Effect of salmon calcitonin on post distal radius fracture pain in postmenopausal women
J Musculoskelet Neuronal Interact. 2015 Jun;15(2):186-9.
Long-term lumiracoxib treatment non-inferior to celecoxib in patients with osteoarthritis
BMC Musculoskelet Disord. 2008 Mar 7;9:32.
Zoledronic acid increases BMD at tibial epiphysis, but not tibial diaphysis
Maturitas. 2014 Mar;77(3):287-93
Zoledronic acid improves health-related quality of life in patients with hip fractures
Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20
Annual infusion of zoledronic acid reduces days of back pain, disability, and bed rest
J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292
Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082
Zoledronate reduces radiation-induced bone collagen degradation in radiation therapy
Clin Transl Oncol. 2015 Jun;17(6):454-61.
Health-related QoL in osteoporotic women improved with zoledronic acid infusions
Bone. 2011 Jun 1;48(6):1298-304. doi: 10.1016/j.bone.2011.03.719. Epub 2011 Mar 21
Etoricoxib and diclofenac similar for blood loss and GI distress rates after THA
Curr Med Res Opin. 2016 Jan;32(1):37-47.
Denosumab noninferior to zoledronic acid in the treatment of bone metastasis
J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22
Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women
J Bone Miner Res. 2014 Jan;29(1):166-72. doi: 10.1002/jbmr.2009.
Zoledronic acid reduces rates of new clinical fractures after hip fracture repair
N Engl J Med. 2007 Nov 1;357(18):1799-809. Epub 2007 Sep 17